China’s Biotech Rise: Clinical Trials, Drug Development & U.S. Competition

China’s biotech industry is expanding rapidly, reshaping clinical trials, drug development, licensing and the global competition for biomedical innovation. What can the United States learn from what’s happening in China? In this episode of the Making Medicine Podcast, host John Stanford sits down with Tim Scott, President & CEO of Biocom, following a biotech delegation trip to Shanghai. Tim shares his firsthand observations of China's life sciences ecosystem, including its approach to clinical trials, patient registries, drug development, biotech investment and pharmaceutical partnerships. The conversation examines why major pharmaceutical companies are increasingly looking to China for innovation, how China's investigator-initiated trial system can accelerate development, and what the scale of China's biotech ecosystem could mean for global medicine. We explore 🔹 Why pharmaceutical companies are increasingly partnering with Chinese biotech 🔹 How China's investigator-initiated clinical trials work 🔹 Patient registries and trial-ready cohorts 🔹 Why China's biotech ecosystem is expanding so quickly 🔹 How drug development and licensing are changing globally 🔹 The role of biosecurity and scientific collaboration 🔹 NIH funding, workforce development and U.S. biotech innovation 🔹 What it takes for the United States to remain competitive in biotechnology 🔹 How AI could reshape the global biotech landscape One of the episode's central ideas comes from Tim's “playing to win” analogy. Rather than focusing only on limiting competitive threats, he argues that U.S. biotech leadership also depends on continued investment in research, clinical trials, manufacturing, workforce development and scientific innovation. The discussion also explores the tension between competition and collaboration. Tim describes China and the United States as both competitors and participants in an increasingly interconnected global life sciences ecosystem. His observations offer a firsthand look at how China's biotech capabilities are evolving and what those changes could mean for drug development worldwide. Join the Conversation⬇️ How significant is China's growing role in global biotech? What factors will determine the future of U.S. leadership in biomedical innovation? And where should the balance between international collaboration, competition and protecting sensitive biotechnology research be drawn? Drop your thoughts in the comments below👇 👍 Subscribe to the Making Medicine Podcast for conversations about the science, business, policy and innovation shaping how medicines are discovered, developed and delivered to patients. If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod Instagram: makingmedicinepod https://www.linkedin.com/showcase/mak... Timestamps 00:00 China Biotech Competition 01:00 California Life Sciences Leadership 07:45 Pharma Licensing Deals in China 13:10 China Clinical Trials & Investigator-Initiated Trials 20:00 Drug Pricing & Biotech Innovation 23:18 Inside Shanghai’s Biotech Ecosystem 25:28 China’s Biotechnology Growth Strategy 35:28 Biosecurity & U.S.-China Biotech Policy 40:20 Competing in Global Biotech 42:10 The Knicks Analogy: Playing to Win 43:20 NIH Funding & U.S. Biotech Innovation 47:35 AI, China & the Future of Biotechnology 49:58 Closing DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #Biotech #ChinaBiotech #DrugDevelopment #ClinicalTrials #biotechnology ‪@NIHgov‬ ‪@US_FDA‬ ‪@HHS‬